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Department of Internal Medicine and Clinical Nutrition, Institute of Medicine 
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Göteborg, Sweden 
ABSTRACT 
Haemophilia A and B are X-linked disorders caused by impaired synthesis of 
coagulation factors VIII and IX, respectively. Women who carry the 
haemophilia trait have about 50 % of normal factor levels. Due to skewed X-
chromosome inactivation, factors in carriers may however range from levels 
corresponding to those in men with haemophilia up to normal levels. One 
hundred and twenty six haemophilia carriers and 90 controls were included in 
the study. In paper I, bleeding tendency was evaluated with a standardised 
bleeding assessment tool. We found increased bleeding tendency among the 
carriers of haemophilia A and B, compared to the control group. The 
bleeding tendency was weakly correlated to FVIII levels. In paper II, health-
related quality of life (HRQOL) in haemophilia carriers was compared to a 
control group and the normative population. HRQOL was evaluated with the 
Short-Form 36 questionnaire. Symptomatic carriers had lower scores in the 
General Health, Social Functioning and Mental Health domains, compared to 
the control group. These differences disappeared when comparisons were 
made with the normative population. Paper III demonstrates that thrombin 
generation potential, evaluated by the calibrated automated thrombography 
method (CAT), did not differ significantly in symptomatic and asymptomatic 
carriers of haemophilia A. The results of paper IV indicate that there was no 
association between bleeding tendency in haemophilia A carriers and 
genotype, evaluated by comparison of null and non-null mutations. In 
conclusion, the results suggest that carriers of haemophilia may have 
increased bleeding tendency, especially during haemostatic stress. Carriership 
did not affect HRQOL in comparison to the normative population. Factor 
levels as well as thrombin generation capacity appear to be inadequate for 
prediction of bleeding tendency in carriers. The bleeding tendency in 
haemophilia A carriers was not influenced by the genotype.  
Keywords: Carriers of haemophilia, bleeding, SF-36, thrombin generation, genotype. 
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund. Hemofili A och B ärvs X-kromosombundet och orsakas av medfödd 
brist på eller avsaknad av koagulationsfaktor VIII respektive IX. Kvinnor som 
bär på anlaget för hemofili har vanligen ca 50 % av normal faktornivå. På grund 
av skev X-kromosom inaktivering kan faktornivån hos bärare variera från låga, i 
motsvarande nivå som hos män med mild hemofili, upp till normal värden.  
Frågeställning. I avhandlingen undersöktes om bärare har en ökad 
blödningsbenägenhet respektive påverkad hälsorelaterad livskvalitet jämfört med 
en kontrollgrupp respektive en svensk normativ population. Vidare undersöktes 
om blödningsbenägenheten var korrelerad till koagulationsfaktornivå. Därtill 
studerades om blödningsbenägenheten hos bärare av hemofili A kunde värderas 
med hjälp av trombingenereringsförmåga respektive utifrån genotyp. 
Metodik. Etthundratjugosex bärare och nittio kontrollpersoner deltog i studien. 
Blödningsbenägenheten värderades med hjälp av ett standardiserat 
intervjuverktyg (BAT) och hälsorelaterad livskvalitet (HRQOL) studerades med 
Short Form-36 (SF-36). Förmågan att generera trombin mättes med CAT-
metod. Sjukdomsorsakande mutationer i genen för FVIII delades in i null 
respektive non-null mutationer.  
Resultat. Vi fann en ökad blödningsbenägenhet hos bärare av hemofili A och B 
jämfört med kontrollgruppen. Blödningsbenägenheten hos bärare av hemofili A 
korrelerade svagt till faktor VIII nivå. Bärare med ökad blödningsbenägenhet 
hade lägre SF-36 poäng inom domänerna för Allmän hälsa, Social funktion och 
Psykiskt välbefinnande, jämfört med kontrollgruppen. Dessa skillnader försvann 
vid jämförelse med den svenska normativa populationen. Blödningsbenägenhet 
hos bärare av hemofili A kunde inte värderas utifrån 
trombingenereringsförmåga och var inte associerad med genotyp uppdelad i null 
och non-null mutationer. 
Slutsatser. Bärare av anlag för hemofili A och B kan ha en ökad 
blödningsbenägenhet, framför allt i situationer som ställer ökat krav på 
blodstillningsförmågan såsom vid operationer och trauma. Faktornivåer 
förefaller inte kunna förutspå blödningsbenägenhet på ett tillräckligt adekvat 
sätt. Bärarskap påverkade inte HRQOL i jämförelse med den normativa svenska 
populationen. Trombingenereringsförmåga skilde inte signifikant mellan bärare 
av hemofili A med och utan ökad blödningsbenägenhet. Genotyp hos bärare av 
hemofili A var inte associerad till blödningsbenägenhet. 
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1 INTRODUCTION 
1.1 Haemostasis 
Haemostasis is a protective mechanism, responsible for keeping blood in a fluid 
state in the vessels as well as preventing blood loss at sites of injury. It is 
essential that haemostasis is activated at the right time, to the right extent and at 
the exact location. Haemostasis is divided into primary haemostasis, including 
vascular constriction and the forming of a platelet plug; secondary haemostasis 
or coagulation; and fibrinolysis, in which the formed clot is dissolved [1].  
1.1.1 Primary haemostasis 
When the endothelial layer is disrupted due to injury, local vasoconstriction 
slows the blood flow and platelets can adhere to the vessel wall. Platelet 
receptors glycoprotein 1b (GPIb) and glycoprotein VI (GPVI) bind with von 
Willebrand factor (VWF) and collagen, respectively, to anchor the platelets to 
the sub-endothelium [2, 3]. The platelets are thus activated. Following 
activation, the platelets change shape, active substances are released from 
granules and the fibrinogen receptors glycoprotein IIbIIIa (GPIIbIIIa) are 
expressed [4]. Additional platelets can then aggregate via inter-platelet fibrinogen 
bridges and a platelet plug is formed [5, 6]. 
1.1.2 Coagulation 
The platelet and its importance in haemostasis were discovered at the end of the 
19th century [7]. The first clotting model was presented after the turn of the 
century. The model contained four components: thromboplastin is released 
from the injured vascular tissue and converts prothrombin into thrombin in the 
presence of calcium; thrombin then converts fibrinogen into fibrin and a clot is 
formed [8]. This four component clotting model could not explain the 
complexity of coagulation and so research continued. In the mid-twentieth 
century many of the remaining coagulation factors (F), i.e. FV, FVII, FVIII, FIX 
and FXI were identified. It was recognized that factor deficiencies may lead to 
more or less severe bleeding disorders. In the 1960s a model was constructed 
representing coagulation as a waterfall. In this model, known as the coagulation 
cascade, each proenzyme is converted to its active state by an upstream-
activated coagulation factor. The coagulation cascade is divided into an intrinsic, 
contact-activated pathway and an extrinsic pathway activated through tissue 
factor (TF). The pathways converge into a common pathway in which activated 
FX (FXa) converts prothrombin into thrombin [9, 10].  
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The current cell-based model of haemostasis indicates that the coagulation 
reactions occur as overlapping steps on cell surfaces rather than as a cascade [11, 
12]. Procoagulant reactions are localized on phospholipid cell surfaces, forming 
and maintaining the platelet and fibrin plug at the site of injury. The cell-based 
model of coagualtion is described in three separate phases: the initiation phase, 
the amplification phase and the propagation phase (fig 1).  
 
 
 
Figure 1. Cell-based coagulation. Roman numerals indicate inactive and active 
coagulation factors. (Reprinted with permission from Oxford University Press) [16] 
 
 
 
 5 
 
The initiation phase occurs on TF-bearing cells. Activated FVII (FVIIa), bound 
to TF, activates small amounts of FIX and FX. FXa binds to FVa and converts 
a small amount of prothrombin to thrombin, initiating coagulation.  
The amplification phase occurs on the surface of activated platelets. The small 
amount of thrombin generated on the TF-bearing cells activates platelets that 
have adhered to the site of injury. Furthermore, thrombin cleaves FV, FVIII 
and FXI into their activated forms.  
The propagation phase occurs on the surface of activated platelets. The tenase 
complex (FIXa/FVIIIa) formed on the platelet surface rapidly starts to generate 
FXa. FXa binds to FVa to form the prothrombinase complex that cleaves 
prothrombin to thrombin. This results in a burst of thrombin generation (TG), 
leading to cleavage of fibrinogen into fibrin to form a clot. Thrombin activates 
FXIII, which enables strengthening of the fibrin clot [13].  
In order to prevent uncontrolled clot formation at the site of an injury, 
coagulation must be restrained. Restraint in terms of space is based on 
coagulation only taking place on pro-coagulant cell surfaces, while time restraint 
is generated by inhibitor pathways. The three major inhibitors are tissue factor 
pathway inhibitor (TFPI), that inhibits TF-FVIIa as soon coagulation has been 
initiated; antithrombin, that inhibits thrombin, FIXa and FXa; and activated 
protein C, that inactivates FVa and FVIIIa in the presence of protein S [14]. 
1.1.3 Fibrinolysis 
Fibrinolysis is initiated once the fibrin clot starts to form. The clot is lysed by 
plasmin originating from fibrin-bound plasminogen. The enzyme tissue 
plasminogen activator (t-PA) is the main activator of plasminogen. t-PA-
induced generation of plasmin is controlled by specific inhibitors, the most 
important of which is plasminogen activator inhibitor 1 (PAI-1) [15]. 
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1.2 Haemophilia 
Haemophilia is one of the oldest recognized hereditary diseases. Throughout the 
centuries, there have been reports of boys and men who have bled to death 
from minor wounds and procedures [17]. The first modern description of 
haemophilia was by J.C. Otto, an American physician, who in 1803 described a 
family consisting of seemingly healthy women and men suffering from a 
congenital bleeding disorder [18]. 
Haemophilia A and B are rare bleeding disorders caused by lack or deficiency of 
functioning FVIII or FIX. Approximately 1 000 Swedish men and boys have 
haemophilia [19]. The ratio between haemophilia A and B is 4:1. The 
characteristic bleeding manifestation in haemophilia is repeated bleeding in 
joints, leading to arthropathy. Haemophilia is classified as severe, moderate or 
mild, according to coagulation factor activity in the blood. In severe 
haemophilia the factor level is < 0.01 kIU/L and joint and muscle bleeding, as 
well as internal bleeding, may occur spontaneously or after minor trauma. In 
moderate haemophilia the factor level is 0.01 - 0.05 kIU/L but bleeding may 
occur spontaneously in this condition as well. In mild haemophilia the factor 
level is > 0.05 to 0.40 kIU/L and spontaneous bleeding is rare, but may occur 
after minor trauma or surgery [20, 21]. By definition, normal plasma contains 1 
IU/mL of each factor. Normal ranges should be established locally, but the 
lower limit is often approximately 0.50-0.60 kIU/L. Replacement therapy in 
haemophilia has improved substantially during the last 40-50 years. Nowadays, 
patients with severe and moderate haemophilia living in high-resource nations 
are treated with prophylactic intravenous recombinant FVIII or FIX 
concentrate two to four times a week to prevent bleeding. Patients with mild 
haemophilia are usually not given prophylactic treatment but are instead treated 
with factor concentrate as needed [22]. In patients with mild haemophilia A, 
desmopressin (DDAVP), a synthetic anti-diuretic hormone analogue, is a 
treatment option since it stimulates the endogenous release of FVIII and VWF 
[23]. Prophylactic treatment with factor concentrate has dramatically reduced 
morbidity and mortality. In the 1950s and 1960s, the median life expectancy 
among men with severe haemophilia was 26 years in Sweden. Today, life 
expectancy is almost the same as for the general population [24, 25]. 
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1.3 Inheritance and genetic aspects of haemophilia 
Haemophilia A and B are X-linked recessive disorders. Women who inherit the 
gene are carriers of the disease trait, while men who inherit the gene have 
haemophilia. All daughters of a haemophilic father will become obligatory 
carriers. There is a 50 % chance that a carrier mother will transmit the defective 
gene to a son, who inherits haemophilia, or to a daughter, who inherits the trait 
(Fig 2).  
 
 
Figure 2. Inheritance patterns of haemophilia (reprinted with permission).
 
One third of new cases of haemophilia A and one fifth of new cases of 
haemophilia B are sporadic rather than familial and are due to a de novo 
mutation [26]. In about 80 % of the sporadic cases, the mutation is also present 
in the carrier mother; in the majority of these cases the mutation has occurred in 
the germ cells of a phenotypically normal grandfather [27].  
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The phenomenon of somatic mosaicism in carriers (onset of mutation in early 
embryogenesis) is fairly common and has clinical implications. A carrier may 
appear to be a non-carrier after testing, although she still risks giving birth to a 
haemophilic boy [28]. Genetic counselling, carrier testing and prenatal diagnosis 
of haemophilia are integrated parts of comprehensive care for this condition. In 
addition to assessment of the coagulation factor level, molecular genetic analysis 
is required to determine carrier status. A normal FVIII:C or FIX:C level does 
not exclude carriership. Direct identification of the mutation known to cause 
haemophilia in the family is preferred, but linkage analysis may be performed 
instead [29, 30].  
The genes of FVIII (F8) and FIX (F9) are located on the distal part of the long 
arm of the X chromosome at Xq28 and Xq27, respectively. The F8 gene, one of 
the larger human genes, was cloned in 1984 [31, 32]. The F9 gene was cloned in 
1982 [33, 34]. After the respective genomic structures were determined, several 
mutations were identified, but it was only when polymerase chain reaction 
(PCR) testing became routine in the late 1980s that full mutation screening 
became feasible. The online FVIII Variant Database and FIX Variant Database 
currently report over 2 000 unique mutations for haemophilia A and over 1 000 
unique mutations for haemophilia B [35, 36]. Since the 1990s, several countries, 
including Sweden, have developed national mutation databases containing 
pedigrees and mutation details for haemophilia families. This resource is 
invaluable for carrier and prenatal screening.  
The mutations in haemophilia may be divided into point mutations, insertions, 
deletions and rearrangements/inversions. In haemophilia A the single most 
important defect is the intrachromosomal inversion involving intron 22 of the 
F8 gene, which results in about 45 % of all severe haemophilia A cases 
worldwide [37]. A similar inversion, involving intron 1 of the F8 gene, is 
reported in about 1-2% of patients with severe haemophilia A [38]. There are no 
rearrangements in haemophilia B equivalent to the large inversions seen in 
haemophilia A. Instead, essentially every haemophilia B family has its own 
unique mutation. Point mutations are the most common gene defect and 
comprise missense mutations (a different amino acid is encoded), nonsense 
mutations (a mutation leading to a stop codon and abrupt termination of 
translation) and splice site point mutations (that corrupt or create a new mRNA 
splice site). Deletions and insertions generally lead to severe and occasionally 
moderate disease. Nonsense mutations lead to severe disease, but the disease 
severity of missense and sometimes splice site mutations depends on the 
location and the particular function of the amino acid affected [39].  
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X-chromosome inactivation (XCI) is the process by which one of the two X-
chromosomes present in females is inactivated to achieve equivalency for X-
linked genes between XX females and XY males. XCI occurs in early embryonic 
life and is then stably inherited through the subsequent somatic cell divisions 
[40]. XCI is defined as skewed if the same allele is inactivated in 75-80 % of the 
cells [41]. Genetic and epigenetic factors have been determined to be involved 
in establishing and maintaining XCI, but the mechanisms are not yet completely 
understood [42, 43]. 
1.4 Carriers of haemophilia 
Due to XCI, haemophilia carriers are expected to have factor levels 
corresponding to about 50 % (0.50 kIU/L) of those found in normal individuals 
[44, 45]. This level is generally considered to be sufficient for normal 
haemostasis [46]. However, a wide range of clotting factor levels is observed in 
carriers. Factor levels may range from very low (< 0.10 kIU/L), the level found 
in males with mild haemophilia, to the upper normal limit (< 2.0 kIU/L) [47].  
Bleeding tendency in carriers has been previously studied, but due to the lack of 
standardised instruments, different in- house questionnaires have been 
constructed for that purpose. Mauser Bunschoten et al. conducted a study in the 
Netherlands in 1988, concluding that bleeding tendency was correlated to 
reduced factor levels [48]. Miesbach et al. reported increased bleeding tendency 
in 19 carriers of haemophilia A with a mean FVIII:C of > 0.50 kIU/L [49]. 
There have also been case reports on increased bleeding tendency among 
carriers with extremely low factor levels [47, 50, 51]. In 2006 Plug et al. 
published the results of a large study in which 274 carriers filled out a 
questionnaire concerning bleeding symptoms. Data on previous FVIII:C and 
FIX:C levels were available in most of the cases. The results suggest an 
increased bleeding tendency among carriers, especially after medical 
interventions or trauma, including at factor levels within the lower normal range 
[52]. Since we recognise that increased bleeding tendency in carriers is a clinical 
problem, we wanted to investigate the Swedish carrier population using a 
standardised bleeding assessment tool (BAT). 
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2 AIMS OF THE STUDIES 
The overall aim was to conduct clinical and basic research to increase our 
understanding of bleeding tendency in carriers of haemophilia and thereby 
improve the care of these women. The specific aims were as follows:  
 
To investigate bleeding tendency among carriers of severe and moderate 
haemophilia A and B, compared to a control group, and to correlate bleeding 
symptoms with levels of FVIII:C and FIX:C (Paper I) 
To investigate the health-related quality of life in carriers of haemophilia A and 
B, compared to the normative Swedish female population (Paper II) 
To investigate whether thrombin generation capacity reflects bleeding tendency 
in carriers of severe and moderate haemophilia A (Paper III) 
To determine possible associations between genotype, i.e. null vs non-null 
mutations, and bleeding tendency in carriers of severe and moderate 
haemophilia A (paper IV) 
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3 METHODS 
Information on study populations, collection of data and laboratory and 
statistical methods are reported in Papers I-IV. In this chapter, selected methods 
are described in detail. 
3.1 Study populations 
The studies were approved by the Regional Research Ethics Committee at 
Gothenburg University (Registry number 450-09). Informed consent was 
obtained from all participants. The study populations were intended to include 
the known population of carriers of severe and moderate haemophilia A and B 
in Sweden. Relative to the number of men with severe and moderate 
haemophilia, there ought to be approximately 450 carriers in Sweden [53]. Two 
hundred and eighty-one adult potential carriers were identified via the 
haemophilia treatment centres (HTC) at Sahlgrenska University Hospital, 
Karolinska University Hospital and Skåne University Hospital/Malmö.  
Paper I 
During 2011, 281 adult potential carriers were invited by mail to participate in 
the study. One hundred and forty-five women agreed to participate. One 
hundred and thirty-six women declined or did not answer the invitation. Eleven 
women were excluded since DNA mutation analysis failed to confirm 
carriership, and eight women dropped out after providing informed consent. 
Each participating carrier was asked to suggest a female friend with neither a 
bleeding disorder nor a family history of bleeding disorders to be part of the 
control group. Ninety controls were included. 
Paper II 
Two of the carriers of severe haemophilia A failed to complete the Short Form 
36 questionnaire (SF-36) and were excluded from participation. One hundred 
and twenty-four carriers and 90 controls participated. The results were 
compared to the results in the general female population reported in the 
Swedish SF-36 Health Survey (n = 4 582) [54, 55]. 
Papers III and IV 
Carriers of haemophilia A were included in Studies III and IV (n = 106). One 
carrier of severe haemophilia was excluded from Study III and one was 
excluded from Study IV, due to lack of plasma and inability to classify an 
existing splice site mutation according to the protocol, respectively. 
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3.2 Assessment of bleeding tendency (Papers I-V)  
During the last decade, there has been interest in developing a tool to 
objectively record and clinically evaluate bleeding symptoms. The Vicenza 
Bleeding Questionnaire (BQ), published in 2005, established the framework and 
scoring key that were later modified into the current BAT developed by the 
International Society of Thrombosis and Haemostasis (ISTH-BAT) [56-58]. The 
original Vicenza BQ was validated to distinguish type 1 von Willebrand disease 
(VWD) from the normal population [56]. The BATs evolved from the Vicenza 
BQ are based on interviews and recollections to report bleeding tendency in a 
standardised manner, but are not validated for a specific diagnosis. The BAT 
used in this thesis was published in 2008 and is a modified and condensed 
version of the original Vicenza BQ [59]. The BAT evaluates the severity and 
frequency of twelve bleeding symptoms and adds them to create a quantitative, 
summative bleeding score (BS). The twelve bleeding symptoms are graded from 
0 to 4, according to severity. A lack of excessive bleeding during surgery, 
delivery or tooth extraction results in a negative score in that specific category. 
Only the worst-case scenario is scored and any situation in which prophylactic 
treatment was given is excluded. Normal BS was determined by interviewing 
100 healthy individuals and ranged from -3 to 3 [59]. Appendix A. 
3.3 Health-related quality of life measurement   
(Paper II) 
Generic health-related quality of life (HRQOL) instruments allow comparisons 
between different populations, as well as with the general population, regardless 
of health disorder. Disease-specific instruments are used to detect changes and 
are suitable for evaluation of treatment. There are validated disease-specific 
instruments for patients with haemophilia, but not for carriers [60, 61]. The 
generic instrument SF-36 was published in 1992 [62]. It has since been 
translated into and validated for several languages, and specific normative data 
for the general population in each country have been developed [63, 64]. The 
questionnaire is self-administered and takes about 10 minutes to complete. It 
consists of 36 questions representing eight domains, in addition to overall 
physical and mental health component summary scores (PCS and MCS) [65]. 
The results in each domain are coded and transformed into scale scores from 0 
(worse possible health) to 100 (best possible health) [55, 65]. The scale scores 
may be transformed into norm-based scores, which reflect the number of 
standard deviations (SD) with which a studied population differs from the age- 
and gender-specific mean in the normative population. Norm-based scores 
permit comparison across scales and populations. Appendix B. 
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3.4 FVIII and FIX coagulant activity measurements 
(Papers I, III, IV) 
FVIII:C was analysed with two methods, the one-stage clotting assay and the 
two-stage chromogenic assay. The one-stage assay is based on the ability of a 
sample to normalise or shorten the delayed clotting of FVIII-deficient plasma in 
an activated partial thromboplastin time (APTT)-based test system. Reference 
plasma calibrated in international units is used to verify the FVIII:C level [66, 
67]. In the chromogenic assay, patient plasma is mixed with thrombin, FX and 
FIXa reagents. FVIII that is activated to FVIIIa converts FX to FXa. FXa 
cleaves a chromogenic substrate and the absorbance is directly proportional to 
the amount of FVIII:C [66, 67]. 
The chromogenic assay may be considered to be the more accurate of the two 
since it does not depend on deficient plasma and the APTT assay. A discrepancy 
between the methods is seen in about 20 – 30 % of the patients with non-severe 
haemophilia A, for which certain mutations of the F8 gene are at least partly 
responsible [68-70]. Most common is an, up to two-fold, lower value with the 
chromogenic assay [71-73]. The opposite does occur, but bleeding symptoms 
seem to be consistent with the chromogenic results [71, 74]. In this thesis, 
reported results are from the chromogenic FVIII:C assay. 
FIX:C was measured with a one-stage clotting assay. The principle is the same 
as in one-stage FVIII:C measurements, but FIX-deficient plasma is used instead, 
and the results are calibrated against a reference FIX plasma sample [66]. 
3.5 Thrombin generation (Papers III - IV) 
The thrombin generation assay (TGA) is considered to reflect the global 
haemostatic capacity in vitro [75, 76]. Routine clotting assays, APTT and 
prothrombin time (PT) measure time to initiation of clot formation and do not 
include the thrombin burst. The amount of thrombin generated is determined 
by the combined activity of pro- and anti-coagulation factors, which means that 
the assay evaluates both hyper- and hypo-coagulable conditions [77]. The 
original TGA was published in the 1950s. The method required continuous sub-
sampling and was technically difficult to perform [78]. Since the 1980s Hemker 
et al. have developed the technique, resulting in the calibrated automated 
thrombin generation assay (CAT) [79, 80].  
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The CAT is based on a slow-acting fluorogenic substrate that enables the 
continuous measurement of TG. The substrate is not affected by the turbidity 
of clot formation or the presence of platelets. The relationship between 
thrombin activity and the fluorescent signal is not linear, due to substrate 
consumption and the inner filter effect of fluorescence measurements. This 
problem is overcome by comparing the fluorescent signal to a constant 
thrombin calibrator with known thrombin activity in a non-clotting plasma 
sample [80]. The results are presented as a thrombogram from which specified 
parameters are calculated (lag-time, time to peak, peak thrombin concentration 
and endogenous thrombin potential (ETP)) (Fig 3). Peak thrombin 
concentration and ETP are considered to best reflect a reduced clotting factor 
level [77]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Parameters of the thrombogram: lagtime (min), time to peak (min), peak 
thrombin (nM), endogenous thrombin potential (ETP) (nM/min). (Reprinted with 
permission from Blackwell Publishing Ltd) [81] 
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3.6 Statistical methods 
The Mann Whitney U test was performed to compare differences between 
groups (Papers I-IV). Fisher´s exact test was used to compare baseline 
characteristics and the prevalence of symptoms between groups (Papers I-II). 
The Bonferroni correction was applied to adjust for multiple comparisons. The 
Spearman rank correlation was used to calculate correlations between variables 
(Papers I and IV). In Paper II the scale scores of the SF-36 were transformed 
into Z-scores by subtracting the mean scale score of the normative population 
sample (matched for age) from the scale score of the study group and dividing 
the difference by the SD in the normative population sample.  
Statistical analyses in Papers I, III and IV were performed with SPSS software 
version 19-22 (SPSS Inc, Chicago, IL, USA). Statistical analyses in Paper II were 
performed with SAS software version 9.0 (SAS Institute Inc, Cary, NC, USA). 
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4 RESULTS 
4.1 Bleeding tendency in carriers of haemophilia 
(Paper I) 
Potential carriers of severe and moderate haemophilia A and B (n = 281) were 
identified via clinical data from the three HTCs in Sweden. One hundred and 
thirty seven (49 %) chose to participate. DNA analyses were performed to 
confirm carriership, disclosing that 126 (92 %) women were eligible for the 
study. These carriers of severe and moderate haemophilia and 90 controls were 
included in the study. One hundred and seven of the participants were carriers 
of haemophilia A and 19 were carries of haemophilia B. The group of non-
participants (n = 144) included women who decided not to participate and 
women who dropped out after providing informed consent (n = 8). The ages 
and diagnosed haemophilia in the families of the participant and non-participant 
carriers are presented in Table 1.  
 
Table 1. Characteristics of the participant and non-participant carriers 
 Participants 
n=126 
Non-
participants 
n=144 
P-value 
Age, years (median, range) 48 (21-83) 45 (18-79) 0.021 
Haemophilia in family (n, %)   0.102 
  Severe HA 93 (74 %) 96 (67 %)  
  Moderate HA 14 (11 %) 22 (15 %)  
  Severe HB 10 (8 %) 15 (10 %)  
  Moderate HB   9 (7 %) 11 (8 %)  
HA, haemophilia A; HB, haemophilia B. 1Mann Whitney U test, 2Fisher’s exact test. 
 
Evaluation of bleeding tendency with the BAT resulted in significantly higher 
total BS in the carrier group, compared to the control group (p < 0.01). The 
median BS was 2 (range -3 to 12) in the haemophilia A carriers and 3 (range -2 
to 12) in the haemophilia B carriers. The median BS in the control group was -1 
(range -3 to 8). A BS < 4 was considered to be within the normal range. The BS 
was < 4 in 82 carriers (65 %) and in all but two women in the control group (98 
%). There was no difference in BS between carriers with known haemophilia in 
the family, compared to carriers with sporadic mutations (p = 0.92). The BS was 
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not correlated to age in the carrier group (r = - 0.07, p = 0.44). There was a 
negative correlation between age and BS in the control group (r = -0.40, p < 
0.001). 
Table 2 shows the proportion of the carriers and controls reporting bleeding 
symptoms. Each bleeding symptom in the BAT is presented; a score ≥ 1 
indicates bleeding symptoms exceeding the normal. The Bonferroni adjustment 
was applied to account for multiple statistical testing. P-values ≤ 0.004 (p= 
0.05/12 tests) were regarded as significant. The carriers reported increased 
tendency to bleed from tooth extraction and surgery, compared to the controls. 
The carriers also suffered nosebleeds, cutaneous bleeding, menorrhagia and 
prolonged bleeding from minor wounds to a greater extent (p < 0.001).  
 
Table 2. The frequency of reported bleeding symptoms among participant 
carriers and controls 
PPH, post-partum haemorrhage; CNS, central nervous system; ns, non-significant. Fisher’s exact 
test. Bonferroni correction for multiple comparisons: p ≤ 0.004 was considered significant. 
 
 
 
 
 Carriers 
n (%) 
Controls 
n (%) 
p-value 
Nosebleed 30/126  (24)   4/90   (4.4) < 0.001 
Cutaneous bleeding 22/126  (17)   1/90   (1.1) < 0.001 
Bleeding from minor wounds 40/126  (32)   0/90 < 0.001 
Oral cavity bleeding 15/126  (12)   2/90   (2.2) ns 
Gastrointestinal bleeding   6/126  (4.8)   2/90   (2.2) ns 
Tooth extraction 31/104  (30)   0/75 < 0.001 
Surgery 25/77    (32)   5/69   (7.2) < 0.001 
Menorrhagia 47/126  (37) 14/90   (16) < 0.001 
PPH 26/108  (24)   7/76   (9.2) ns 
Muscle haematoma 31/126  (25) 18/90   (20) ns 
Haemarthrosis   4/126  (3.2)   2/90   (2.2) ns 
CNS bleeding   1/126  (0.8)   0/90 ns 
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Table 3 presents treatments given to the carriers due to bleeding complications 
or in order to prevent bleeding. Twenty-four carriers (19 %) had received 
erythrocyte transfusion on some occasion, compared to four women (4.4 %) in 
the control group. Furthermore, one woman (1.1 %) in the control group had 
been given a plasma transfusion and seven (7.8 %) had been treated with 
tranexamic acid due to bleeding. The controls had not received any prophylactic 
treatment. 
 
Table 3. Prophylactic treatment and treatment given due to bleeding reported 
by the carriers  
 Prophylactic 
treatment 
Treatment due to 
bleeding 
Erythrocyte concentrate  24/126     (19 %) 
Plasma    1/126   (0.8 %)   4/126     (3.2 %) 
FVIII/IX factor concentrate    7/126   (5.6 %)   3/126     (2.4 %) 
Desmopressin 1 15/107   (14 %)   6/107     (5.6%) 
Tranexamic acid 2 26/126   (21 %) 34/126     (27 %) 
1Only applicable for carriers of haemophilia A. 2Twelve carriers received tranexamic acid as 
prophylactic treatment as well as due to bleedings. 
 
4.2 Health-related quality of life in carriers of 
haemophilia (Paper II) 
The respective numbers of carriers and controls who completed the survey were 
124 and 90. The entire group of carriers and the subgroup of symptomatic 
carriers (defined as BS ≥ 4) were compared to the control group. Demographic 
data and clinical characteristics of the carriers, the subgroup of symptomatic 
carriers and the controls are presented in Table 4. There was a significant 
difference in BS between the two carrier groups and the control group (p < 
0.01). The groups were similar in terms of age, marital status, number of 
children, education, employment and co-morbidity.  
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Table 4. Characteristics of the carriers, the subgroup of carriers with 
increased bleeding tendency and the controls 
 
HA, Haemophilia A; HB, Haemophilia B; BS, bleeding score; BMI, body mass index; VTE, 
venous thromboembolism; ns, non-significant. *Cardiovascular includes hypertension. 1Mann 
Whitney U test, 2Fisher’s exact test 
 
When comparing the scale scores of the eight SF-36 domains in the entire group 
of carriers with those in controls, a significant difference was seen in the Mental 
Health domain (p = 0.048). When the same comparison was made between the 
group of symptomatic carriers and the control group, there were significant 
differences in the General Health domain (p = 0.012), the Social Functioning 
domain (p = 0.021) and the Mental Health domain (p = 0.043). The scale scores 
in each domain were transformed into Z-scores and compared with the aged-
matched Swedish normative female population (n = 4 582). The Z-score 
represents the difference between the scale score and the normative population 
 Carriersa 
n = 124 
Carriers, BS ≥ 4b 
n = 44 
Controlsc 
n = 90 
p-value  
a vs. b       
 
a vs. c 
Age, years median (range)1   48 (21-83)  48 (21-72) 52 (25-90) ns ns 
Carriers of HA, n (%) 105 (85)  36 (82)    NA   
Carriers of HB, n (%)   19 (15)   8 (18)    NA   
Family with haemophilia, 
 n (%) 
   
  71 (57) 
           
  4 (54) 
 
   NA 
  
BS, median (range) 1  2 (-3 to12)  6.5 (4 - 12) -1 (-3 to 8) <0.001 <0.001 
BMI > 30, n (%) 2   22 (18)   9 (20)  8 (8.8) ns ns 
Current smoker, n (%) 2   14 (11)   5 (11)  5 (5.6) ns ns 
Marital status, n (%) 2    ns ns 
    Married/cohabiting    89 (72) 35 (80) 72 (80)   
    Single/divorced/widowed      35 (28)   9 (20) 18 (20)   
Children, n (%) 2    ns ns 
     0  11 (8.9)  2 (4.5) 14  (16)   
     1-2  87 (70) 32 (73) 53  (59)   
     3-5  26 (21) 10 (23) 23  (26)   
Education level, n (%) 2    ns ns 
     Elementary school  33 (27) 13 (30)  16 (18)   
     Secondary school  41 (33) 12 (27)  26 (29)   
     University  50 (40) 19 (43) 4 8 (53)   
Employment, n (%)2    ns ns 
     Gainfully employed  97 (78) 38 (86)  79 (88)   
     Student   2 (1.6)     1 (1.1)   
     Retired 
     Unemployed 
19 (15) 
  6 (4.8) 
4 (9.1) 
2 (4.5) 
 10 (11) 
 
  
Comorbidities, n (%)2    ns ns 
     Cardiovascular * 11 (8.9) 5 (11)   11(12)   
     Diabetes 5 (4.0) 3 (6.8)    2 (2.2)   
     Cancer 5 (4.0) 1 (2.3)    5 (5.6)   
     Cerebrovascular 1 (0.8)     2 (2.2)   
     VTE      1 (1.1)  
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mean, expressed as SD units. A Z-score is negative when the scale score is 
below the normative population mean and positive when it is above this mean. 
There was no significant difference between Z-scores in the entire group of 
carriers and in the control group (Fig 4). There was a significant difference 
between the Z-scores in the group of symptomatic carriers and the control 
group in the General Health (p = 0.008), Social Functioning (p = 0.04) and 
Mental Health (p = 0.048) domains (Fig 5). Each of these differences was, 
however, less than 0.4 SD from the mean of the normative population. 
 
 
 
Figure 4. Differences in Z-scores between the entire group of carriers and the 
control group for each SF-36 domain.  Dark bars, carriers; grey bars, controls. The 
zero line represents Swedish age-matched normative data. PF, Physical Functioning; 
RP, Role Physical; BP, Bodily Pain; GH, General Health; VT, Vitality; SF, Social 
Functioning; RE, Role Emotional; MH, Mental Health. Mann Whitney U test. 
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Figure 5.  Differences in Z-???????????????????????????????????????????????????????
4) and the control group for each SF-36 domain. Dark bars, carriers; grey bars, 
controls. The zero line represents Swedish age-matched normative data. PF, 
Physical Functioning; RP, Role Physical; BP, Bodily Pain; GH, General Health; VT, 
Vitality; SF, Social Functioning; RE, Role Emotional; MH, Mental Health. Mann 
Whitney U test. (* p < 0.05). 
 
 
4.3 Laboratory evaluation of bleeding tendency 
(Papers I, III and IV) 
4.3.1 Factor levels and bleeding tendency 
The median FVIII:C level among the haemophilia A carriers was 0.58 kIU/L 
(intra-quartile range (IQR): 0.42-0.78) and the median FIX:C level among the 
haemophilia B carriers was 0.50 kIU/L (IQR: 0.33-0.67). A basic laboratory 
evaluation of haemostasis in the carriers was performed (Table 5). The subgroup 
???????????????????????????????????????????????????????????????????????????????
a normal bleeding tendency (BS < 4). There was no significant difference 
between the two groups, including FVIII:C and FIX:C levels. 
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Table 5. Comparison of laboratory data between carriers with and without 
increased bleeding tendency 
 Carriers, 
BS < 4 
n = 82 
Carriers, 
BS ≥ 4 
n = 44 
 Reference 
values1 
p-
value 
 
Haemoglobin (g/L)  133 (127-138)   134 (127-141)  117-153 ns 
Platelets (x 109/L)  265 (217-306)   262 (223-298)  165-385 ns 
PT (INR) 
APTT (s) 
  1.0 (1.0-1.1) 
   38 (36-40) 
   1.0 (1.0-1.1) 
    39 (35-42) 
 <1.2 
30 - 42 
ns 
ns 
Fibrinogen (g/L)   3.1 (2.8-3.6)    3.2 (2.9-3.6)  2.0 - 4.5 ns 
FVIII:C (kIU/L)2 0.62 (0.44-0.88)  0.52 (0.37-0.71)  0.50 - 2.00 ns 
FIX:C (kIU/L)3 0.56 (0.45-0.82)  0.36 (0.24-0.62)  0.60 - 1.30 ns 
VWF:RCo (kIU/L) 0.98 (0.80-1.28)    1.0 (0.84-1.21)  0.40 - 1.20 ns 
1Reference values from the Laboratory of Clinical Chemistry, Sahlgrenska University Hospital. 
2Carriers of haemophilia A (n=107), 3Carriers of haemophilia B (n=19). Results are presented as 
median and IQR. Mann Whitney U test.  
 
 
 
There was a weak correlation between BS and FVIII:C levels in haemophilia A 
carriers (r = -0.36, p < 0.001 ). The BS was not correlated to FIX:C levels in 
haemophilia B carriers (r = -0.33, p = 0.17) (Fig 6). Although the factor level of 
0.40 kIU/L is the upper limit defining haemophilia, the figure demonstrates an 
increased BS in a subgroup of carriers with factor levels within the lower normal 
range (Fig 5). There was a weak correlation between age and FVIII:C levels (r = 
0.24, p = 0.015).The scatterplot (Fig. 7) indicates that the highest FVIII:C levels 
were found in carriers aged 60 years and up. No correlation was observed 
between FIX:C and age (r = 0.39, p = 0.10). 
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Figure 6. The relationship between coagulation factor activity and BS. Correlation 
between FVIII:C and BS in carriers of haemophilia A: r = -0.36, p < 0.001. Correlation 
between FIX:C and BS in haemophilia B carriers: r = -0.33, p = 0.17. Horizontal line 
?????????????????????????????????????????????????????????????????????????????????????????????
kIU/L.  
 
Figure 7. The relationship between FVIII:C levels and age in haemophilia A carriers,      
r = 0.24, p = 0.015 .  
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4.3.2 Thrombin generation and bleeding tendency 
Since the bleeding tendency among the carriers was not explained by factor 
levels, the next step was to evaluate in vitro global haemostasis. TG was 
analysed in platelet-poor plasma (PPP) with the CAT assay. The analysis was 
performed in haemophilia A carriers (n=106), who were divided into groups 
according to bleeding tendency. The first group consisted of carriers with BS < 
4 (n = 71) and the second group comprised carriers with BS ≥ 4 (n = 35). Fig. 8 
shows the results of the ETP and peak thrombin assays, in which 1 pM TF was 
used as a trigger. There was no significant difference in ETP (p = 0.52) or peak 
thrombin (p = 0.38) between the groups of carriers. The carriers were then 
divided into groups according to FVIII:C level. The first group consisted of 
carriers with FVIII:C ≥ 0.50 kIU/L (n = 67), while the second group had 
FVIII:C < 0.50 kIU/L (n = 39). TF 1 pM was used as trigger. The carrier group 
with low FVIII:C levels had significantly lower ETP (p < 0.001) and peak 
thrombin (p < 0.01) values (Fig 9). FVIII:C correlated with both ETP (r = 0.34, 
p < 0.001) and peak thrombin (r = 0.50, p < 0.001). There was no correlation 
between age and CAT results (data not shown). 
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Figure 8. Box plot analyses of the TG (CAT) results (ETP and peak thrombin) in 
carriers with normal bleeding scores, compared to carriers with increased bleeding 
scores. Mann Whitney U test. 
 
Figure 9. Box plot analyses of the TG (CAT) results (ETP and peak thrombin) in 
carriers with normal FVIII:C, compared to carriers with low FVIII:C. Mann-
Whitney U test. 
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4.3.3 Genotype and bleeding tendency 
 
The rationale behind dividing the mutations into null and non-null is that a null 
mutation results in the absence of a gene product or of a gene product 
functional at the phenotypic level. The F8 gene mutations identified in the 
haemophilia A carriers are presented in Table 6.  
A majority of the null mutations (99 %) were found in carriers belonging to 
families with severe haemophilia. There were no significant differences in BS 
between the carriers with null and non-null mutations (p = 0.37). There was a 
significant difference in FVIII:C levels between the carrier groups but, 
unexpectedly, FVIII:C levels in the null mutation group were significantly higher 
than those in the non-null group (p = 0.013). There was no significant 
difference in the CAT assay results (peak thrombin and ETP) between the 
groups. 
 
 
Table 6. Distribution of F8 mutations in the 106 carriers of haemophilia A 
Mutation group (n=106) n (%) 
F8 null mutations  
   Inversions 51 (48) 
   Nonsense mutations 8 (7.5) 
   Small deletions/insertions outside poly-A runs 16 (15) 
F8 non-null mutations  
   Missense mutations 25 (24) 
   Small deletions/insertions within poly-A runs 5 (4.7) 
   Splice site mutations on non-conserved nucleotides 1 (0.9) 
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5 DISCUSSION 
5.1 Methodological considerations 
5.1.1 Study sample 
Our goal was to identify and investigate the Swedish population of carriers of 
severe and moderate haemophilia. An initial problem was to locate potential 
carriers since they seek medical care at hospitals across the country. Carriers 
with close male relatives diagnosed with haemophilia and carriers with bleeding 
problems themselves are registered at a HTC to a higher degree. Almost 300 
adult potential carriers were identified, of whom approximately half agreed to 
participate in the studies. It is not unlikely that carriers with a history of bleeding 
and those with close relatives with haemophilia were more inclined to 
participate. This selection bias may have resulted in an overestimate of the 
incidence of bleeding symptoms in the carrier population. Only six of the 
participating carriers were of non-European origin and the study population was 
not representative of the Swedish carrier population in that sense. This may 
have influenced the results since the perception of bleeding may be different 
due to cultural differences and due to growing up as a haemophilia carrier in a 
developing country. 
5.1.2 Bleeding assessment tool (Papers I-IV) 
The evaluation of bleeding tendency is essential to this thesis. The symptoms 
reported may be influenced by personality, education level and, not least, by 
family history, since belonging to a family of bleeders may have an impact on 
how bleeding symptoms are regarded. Moreover, normal subjects report 
bleeding symptoms as well [82]. The BAT was developed to standardise the 
diagnostic criteria of type 1 VWD [56] and has subsequently been adapted by 
investigators to collect data on bleeding in several studies [83-86]. Since we 
conducted our study, the BAT has been developed further by the ISTH [58]. 
The current optimized version, the ISTH-BAT, evaluates frequency of bleeding 
to a larger extent than the severity of each bleeding symptom [58, 87]. Had we 
used the ISTH-BAT, it might possibly have yielded results with a higher degree 
of specificity in our cohort of carriers. 
5.1.3 Thrombin generation assay (Papers III - IV) 
The CAT assay is a research tool and inter-laboratory variability is high. Since 
our studies were performed, considerable work has been done to produce 
standardised protocols in an attempt to overcome problems with the method 
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[88-91]. Protocol standardisation includes the source and concentration of TF 
and reagents used [77, 92, 93]. Variations in venepuncture procedure and 
preparation of plasma have also been shown to influence the assay results. The 
use of corn trypsin inhibitor (CTI), at least at low TF concentrations, is 
suggested to reduce risk of contact activation through the intrinsic pathway [94-
96]. This was not taken into consideration when our analyses were performed. 
5.2 Individual papers 
5.2.1 Bleeding tendency (Paper I) 
The carriers reported more provoked and spontaneous bleedings than the 
women in the control group. This includes bleeding after surgery, from tooth 
extraction and menorrhagia, as well as nosebleed, cutaneous bleedings and 
excessive bleeding from minor wounds. The frequency of PPH was not 
significantly different between the carriers and the control group, provided that 
the carriers of haemophilia A and B were not separated. The increased 
frequency of PPH among haemophilia B carriers can possibly be explained by 
the increase in FVIII:C, but not FIX:C, that occurs during pregnancy in both 
carriers and the normal population [97-100]. Earlier studies have demonstrated 
that carriers with decreased factor levels may have symptoms similar to those in 
men with mild or, in rare cases moderate, haemophilia [48, 49, 51]. In 2006 Plug 
et al. published a large study of bleeding tendency in Dutch carriers [52]. 
Carriers with factor levels within the lower normal range reported increased 
bleeding tendency, particularly associated with surgery and tooth extractions, 
compared to carriers with factor levels above 0.60 kIU/L. Our results are in 
agreement with these findings. A study similar to ours was published in 2014 by 
Paroskie et al. [83]. The authors reported increased bleeding tendency, in line 
with our results, when assessing 44 carriers of haemophilia A with a median 
factor level within the normal range. In conclusion: carriers who phenotypically 
are defined as having mild haemophilia, but also carriers with factor levels 
within the lower normal range may have increased bleeding tendency, especially 
related to haemostatic stress such as surgery and trauma. 
5.2.2 Health-related quality of life (Paper II) 
The concept of health is defined as physical, psychological and social wellbeing 
and not merely the absence of disease [101]. Generic instruments are used, 
irrespective of a specific disorder, and allow comparisons between patient 
groups and the general population, but they do not yield patterns of symptoms 
related to specific disorders. The results of our study using the SF-36 
questionnaire demonstrated a difference between symptomatic carriers and the 
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control group. The carriers scored significantly lower in the General Health, 
Social Functioning and Mental Health domains. However, these differences are 
within a SD from the mean of the Swedish normative female population. These 
findings are reassuring, since bleeding generally occurs during specific occasions 
and not in everyday life. Menorrhagia is an exception, since it is a symptom 
typically recurring from menarche to menopause in women with increased 
bleeding tendency. Menorrhagia has been demonstrated to have a negative 
HRQOL impact in both women with and without increased bleeding tendency 
[102-104]. The median age of our carriers was 48 years; a large proportion of the 
women were thus postmenopausal. Data on HRQOL in haemophilia carriers 
are limited. In a study similar to ours, the authors present a comparison of SF-
36 results obtained from 42 haemophilia A carriers and a control group [105]. 
The carriers scored significantly lower in the Bodily Pain and General Health 
domains than the control group, but the results were not compared to the 
normative population. VWD is the most common inherited bleeding disorder. 
The HRQOL of 317 women with VWD was determined and compared to the 
normative population in a nationwide Dutch study [106]. A majority of the 
women had type 1 VWD of moderate severity. The entire population of women 
with VWD scored significantly lower in the General Health and Vitality 
domains, compared to the normative Dutch population; however, the Z-scores 
were lower than 0.3. These data appear to confirm that mild bleeding disorders 
do not have an impact on HRQOL, compared to the normative population. 
5.2.3 Coagulation factor levels (Paper I) 
FVIII:C and FIX:C levels are probably not good predictors of bleeding 
phenotype in carriers of haemophilia [52, 83]. VWD was excluded in our cohort 
of carriers, but other factors, such as inherited thrombophilia and mild platelet 
disorders, have not been ruled out as contributors to the phenotype [107, 108]. 
Furthermore, there is an intra-individual variation in FVIII:C levels in relation to 
oestrogen levels in women, and reports suggest that FVIII:C levels are highest 
during the luteal phase of the menstrual cycle [109-111]. The influence on 
FVIII:C levels due to hormonal therapy depends on the content of oestrogen 
[112]. However, our study was not designed to take this into account and 
menstrual cycle status was not recorded. Hormonal fluctuations might have 
affected FVIII:C levels. The plasma concentration of several coagulation 
factors, including FVIII:C and FIX:C, increase significantly with age in healthy 
humans [113, 114]. The carriers in our cohort with FVIII:C levels above 1.50 
kIU/L were all more than 60 years of age, which may have influenced the 
results since the BAT assesses lifelong bleeding tendency. 
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5.2.4 Thrombin generation assay (Paper III) 
Thrombin is a key enzyme in the coagulation system and TG measurement may 
reflect the in vitro overall coagulation capacity of an individual more accurately 
than traditional coagulation tests. Studies have demonstrated a relationship 
between the severity of a bleeding tendency and the ETP, regardless of factor 
levels. In patients with rare congenital coagulation factor deficiencies, a severe 
phenotype was associated with an ETP < 20 % of normal [115]. There is an 
association between phenotype and ETP in haemophilia as well [116, 117]. The 
TG assay appears to distinguish between bleeding phenotypes in individuals 
with the same factor levels in both severe and non-severe haemophilia A [118, 
119]. We therefore investigated whether bleeding tendency in the haemophilia A 
carriers could be predicted by the results of the CAT assay. However, the TG 
potential in symptomatic carriers was not different from that in carriers with 
normal bleeding tendencies. In comparison to Al Dieri’s material, a vast majority 
of the carriers in our study had milder bleeding tendencies, which presumably 
contributed to the results. The FVIII:C levels in our study correlated with the 
ETP and peak thrombin, concurring with studies in the haemophilia setting [77, 
120]. 
5.2.5 Genotype (paper IV) 
Type of mutation is a strong predictor of bleeding in men with haemophilia [35, 
36, 121]. DNA is, however, primarily tested in potential carriers for the purpose 
of genetic counselling. The association between type of mutation and bleeding 
tendency in carriers is not well studied. Miesbach et al. have published data on 
bleeding tendency, FVIII:C levels and genotype in 43 haemophilia A carriers. 
The group of carriers with menorrhagia and easy bruising had null-mutations to 
a higher degree than the asymptomatic carriers [49]. Our results suggest no such 
association. Indeed, in contrast to men with haemophilia A, carriers have one 
normal F8 gene producing FVIII. In line with this reasoning, studies have 
shown conflicting results concerning whether factor levels differ between 
carriers of severe, moderate and mild haemophilia [44, 122, 123]. 
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6 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
Carriers of moderate and severe haemophilia A and B had increased BS, 
compared to a control group. Increased bleeding tendency was found not only 
in a subgroup of carriers with low factor levels but also in a subgroup of carriers 
with factor levels within the lower normal range. Our findings suggest that it 
may be beneficial for symptomatic carriers to be followed up at a HTC on a 
regular basis, in order to prevent excessive bleeding. Our findings also suggest 
that healthcare professionals need to be aware that women belonging to families 
with haemophilia might have increased bleeding tendency as well (Paper I). 
HRQOL, measured with SF-36, in carriers of haemophilia A and B did not 
differ from that in the normative Swedish female population. This finding 
suggests that carriership does not affect HRQOL (Paper II). 
TG capacity, measured with CAT, did not differ between symptomatic and 
asymptomatic carriers of haemophilia A. This finding indicates that CAT may 
not be a useful tool to assess bleeding tendency or to predict bleeding risk 
among carriers of haemophilia A (Paper III). 
The bleeding tendency in carriers of haemophilia A was not associated with 
genotype, evaluated by comparison of null and non-null mutations. The 
genotype in carriers is probably not a good predictor of bleeding tendency since 
carriers, in contrast to men with haemophilia, have a normal allele producing 
FVIII to a varying degree (Paper IV). 
 
Further studies to evaluate bleeding tendency and bleeding risk are important in 
order to provide good care to carriers of haemophilia. Firstly, studies are needed 
to confirm our results on bleeding tendency, especially in carriers with factor 
levels within the normal lower range. Secondly, a BAT validated for haemophilia 
carriers to predict bleeding risk needs to be developed. Thirdly, laboratory 
methods to evaluate bleeding tendency and predict bleeding risk require 
improvement. Finally, prospective studies are needed to evaluate haemostasis 
and carriers’ ability to mobilise coagulation factors during and after surgery and 
delivery. This would be of particular interest in symptomatic carriers with factor 
levels within the lower normal range.    
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APPENDIX 
A. Bleeding assessment tool [59] 
Symptom Score      
-1 0 1 2 3 4 
Epistaxis  No or trivial 
(<5) 
>5/year or more 
than 10’ 
Consultation only Packing or 
cauterization or 
antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Cutaneous  No or trivial >1cm and no 
trauma 
Consultation only   
Bleeding from 
minor wounds 
 No or trivial 
(< 5’) 
>5/year  or > 5’ Consultation only Surgical 
haemostasis 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Oral cavity  No Referred at least 
one 
Consultation only Surgical 
haemostasis 
or antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
GI-bleeding  No Associated with 
ulcer, portal 
hypertension, 
haemorrhoids, 
angiodysplasia 
Spontaneous Surgical 
haemostasis, 
blood 
transfusion, 
replacement 
therapy, 
desmopressin, 
antifibrinolytic 
 
Tooth extraction No bleeding in 
at least 2 
extractions 
None done or 
no bleeding in 
1 extraction 
Reported, no 
consultation 
Consultation only Resuturing or 
packing 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Surgery No bleeding in 
at least 2 
surgeries 
None done or 
no bleeding in 
1 surgery 
Reported, no 
consultation 
Consultation only Surgical 
haemostasis or 
antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Menorrhagia  No Consultation 
only 
Antifibrinolytics, 
pill use 
Dilation & 
curettage, iron 
therapy, ablation 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin or 
hysterectomy 
Postpartum 
haemorrhage 
No bleeding in 
at least 2 
deliveries 
None done or 
no bleeding in 
1 delivery 
Consultation 
only 
Dilation & 
curettage, iron 
therapy, 
antifibrinolytics 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Hysterectomy 
Muscle 
haematomas 
 Never Post trauma, no 
therapy 
Spontaneous, no 
therapy 
Spontaneous or 
traumatic, 
requiring 
desmopressin or 
replacement 
therapy 
Spontaneous or 
traumatic, 
requiring surgical 
intervention or 
blood 
transfusion 
Haemarthrosis  Never Post trauma, no 
therapy 
Spontaneous, no 
therapy 
Spontaneous or 
traumatic, 
requiring 
desmopressin or 
replacement 
therapy 
Spontaneous or 
traumatic, 
requiring surgical 
intervention or 
blood 
transfusion 
CNS bleeding  Never   Subdural, any 
intervention 
Intracerebral, 
any intervention 
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B. SF-36 Measurement model [65] 
Scales Items  
Physical functioning P(PF) 3a.   Vigorous activities 
3b.   Moderate activities 
3c.   Lift, carry groceries 
3d.   Climb several flights 
3e.   Climb one flight 
3f.    Bend, kneel 
3g.   Walk mile 
3h.   Walk several blocks 
3i.    Walk one block 
3j.    Bathe, dress 
 
 
 
 
 
 
 
 
 
 
Physical 
Health 
Role-Physical (RP) 4a.   Cut down time 
4b.   Accompished less 
4c.   Limited in kind 
4d.   Had difficulty 
Bodily pain (BP) 7.     Pain-magnitude 
8.     Pain-interfere 
General health (GH) 1.     EVGFP rating 
11a. Sick easier 
11b. As healthy 
11c. Health to get worse 
11d. Health excellent 
Vitality (VT) 9a.   Pep/life 
9e.   Energy 
9g.   Worn out 
9i.    Tired 
 
 
 
 
 
 
Mental 
Health 
Social Functioning (SF) 6.     Social-extent 
10.   Social-time 
Role-Emotional (RE) 5a.   Cut down time 
5b.   Accomplished less 
5c.   Not careful 
Mental Health (MH) 9b.   Nervous 
9c.   Down in dumps 
9d.   Peaceful 
9f.    Blue/sad 
9h.   Happy 
 
